{"id":"W4410818934","doi":"10.1200/jco.2025.43.16_suppl.7015","title":"Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year (yr) follow-up of STARGLO.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"Roche","keywords":"Medicine; Gemcitabine; Diffuse large B-cell lymphoma; Oxaliplatin; Refractory (planetary science); Internal medicine; Lymphoma; Oncology; Chemotherapy; Cancer; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001302023,0.000565321,0.001121799,0.0002829565,0.0002481752,0.0007915213,0.0004588438,0.000713318,0.001829853],"category_scores_gemma":[0.0007671571,0.0003488147,0.001535287,0.0003801967,0.0004602947,0.0008369911,0.0004530421,0.001362369,0.0003903556],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000916298,"about_ca_system_score_gemma":0.0007354936,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009463519,"about_ca_topic_score_gemma":0.003379581,"domain_scores_codex":[0.9996204,0.0001506393,0.00003295863,0.00007812465,0.000031475,0.00008631905],"domain_scores_gemma":[0.9994196,0.0000796834,0.0001766135,0.00004830706,0.00002355551,0.0002523315],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8368435,0.008716117,0.04038783,0.0005156053,0.002422346,0.0001869867,0.0002060607,0.002138927,0.008743661,0.0001188378,0.002405229,0.09731491],"study_design_scores_gemma":[0.2870905,0.5319259,0.1658703,0.0001098672,0.003696929,0.0006330239,0.0001936114,0.00206588,0.002781516,0.0004463948,0.005124934,0.00006109486],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9956364,0.002322717,0.0001491763,0.0001590094,0.00004511904,0.0003239784,0.0006434281,0.00002986818,0.0006903138],"genre_scores_gemma":[0.9963737,0.0008157233,0.0002817323,0.0003811379,0.00004621457,0.0002338181,0.001342633,0.000006263858,0.0005187545],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001829853,"threshold_uncertainty_score":0.006885827,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02759127132732363,"score_gpt":0.3500205164640214,"score_spread":0.3224292451366978,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}